Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exact Sciences Corp (NASDAQ: EXAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Exact Sciences’ cancer screening and diagnostic testing business, financial performance, and significant corporate events.
For EXAS, key filings include current reports on Form 8-K that describe material developments. One Form 8-K reports quarterly financial results, including revenue contributions from the Screening grouping, which encompasses Cologuard tests and PreventionGenetics, and from the Precision Oncology grouping, which includes global Oncotype DX and therapy selection tests. These filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, and free cash flow, along with reconciliations and management’s rationale for using these measures.
Another important 8-K details the Agreement and Plan of Merger among Exact Sciences, Abbott Laboratories, and a wholly owned Abbott subsidiary. This filing explains the structure of the proposed merger, the per‑share cash consideration to be paid for Exact Sciences common stock, the treatment of equity awards, the conditions to closing, termination rights, and any potential termination fee. It also notes that Exact Sciences’ board of directors unanimously approved the merger agreement and recommends that stockholders adopt it, subject to customary conditions.
Additional 8-K filings describe a collaboration and license agreement with Freenome Holdings, Inc. for blood‑based colorectal cancer screening tests, as well as other corporate announcements furnished as exhibits, such as earnings press releases and investor communications. These documents provide context on how Exact Sciences is expanding its portfolio in blood‑based screening and multi‑cancer early detection.
On Stock Titan, investors can review these SEC filings as they are made available through EDGAR. AI‑powered tools can help summarize lengthy disclosures, highlight key terms of material agreements, and surface notable changes in guidance, capital structure, or strategic direction, enabling users to quickly understand the implications of new EXAS filings.
Exact Sciences Corporation has called a virtual special meeting for stockholders to vote on its proposed acquisition by Abbott Laboratories for
Stockholders of record as of
EXACT Sciences Corp. (EXAS) executive vice president and general manager of Screening, Jacob A. Orville, reported an open‑market sale of company stock. On 11/19/2025, he sold 5,000 shares of EXAS common stock at a price of $75 per share in a transaction coded "S" for sale.
After this transaction, Orville beneficially owns 23,237 shares of common stock directly and 1,490 shares indirectly through a 401(k) plan, for a total of 24,727 common shares. In addition, he holds an aggregate of 79,661 vested and unvested stock options and restricted stock units, each RSU representing a contingent right to receive one share of common stock.
The filing notes that the reported sale was carried out under a Rule 10b5‑1 trading plan that Orville entered into on May 27, 2025, indicating the trade was made pursuant to a pre‑arranged plan.
Exact Sciences Corp. executive James Herriott, SVP, General Counsel & Secretary, reported selling 1,000 shares of the company’s common stock on 11/19/2025 at a price of $70 per share under a pre-arranged Rule 10b5-1 trading plan entered into on March 3, 2025. After this sale, he beneficially owns 11,585 shares directly and 1,556 shares held in a 401(k) plan, for a total of 13,141 shares. In addition, he holds an aggregate of 37,434 vested and unvested stock options and restricted stock units, each unit representing the right to receive one share of common stock.
Exact Sciences Corporation agreed to be acquired by Abbott Laboratories in an all-cash merger. Each share of Exact common stock will be converted at closing into the right to receive $105.00 in cash, subject to the terms and conditions of the merger agreement. Exact’s board of directors unanimously approved the deal and plans to recommend that stockholders adopt the merger agreement.
The transaction must be approved by a majority of Exact’s outstanding shares and obtain required antitrust and other regulatory clearances, with no law or order prohibiting completion. The merger agreement includes customary covenants restricting Exact’s ability to seek alternative transactions and requires Exact to operate in the ordinary course until closing. Either side can terminate under specified circumstances, including if the merger is not completed by November 19, 2026, and Exact may owe Abbott a termination fee of $628,694,446 in certain situations, such as accepting a superior proposal.
Exact Sciences (EXAS) executive James Herriott, SVP, General Counsel & Secretary, reported the sale of 1,500 shares of common stock at $70.08 on 11/04/2025. The transaction was made under a Rule 10b5-1 trading plan entered on March 3, 2025.
After the sale, Herriott beneficially owned 12,585 shares directly and 1,556 shares held indirectly in a 401(k) plan. He also holds an aggregate 37,434 vested and unvested options and restricted stock units.
Exact Sciences (EXAS) reported an insider transaction by EVP, GM, Precision Oncology Brian Baranick. He sold 2,858 shares of common stock on 11/04/2025 at $70.08 per share, executed pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.
Following the sale, he beneficially owned 22,368 shares directly and 670 shares held in a 401(k) plan. In addition, he holds an aggregate of 73,080 vested and unvested options and restricted stock units, with each RSU representing a contingent right to receive one share of common stock.
Exact Sciences (EXAS) filed its quarterly report showing higher revenue and a narrower loss. Revenue for the quarter reached $850.739 million, up from $708.655 million a year ago, driven by both Screening and Precision Oncology. Net loss improved to $19.594 million from $38.236 million. Gross profit was $583.929 million.
By segment, Screening generated $666.240 million, while Precision Oncology contributed $184.499 million. For the first nine months, operating cash flow was $339.749 million, reflecting stronger collections and working capital. The company ended the quarter with $789.037 million in cash and cash equivalents and $214.058 million in marketable securities, totaling $1,003.095 million.
Convertible debt consisted of four series with a net carrying amount of $2.325 billion, and the company settled $249.172 million of 2025 notes in cash earlier in the year. Stockholders’ equity stood at $2.501 billion. Shares outstanding were 189,452,459 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Exact Sciences Corporation announced its financial results for the quarter ended September 30, 2025, and furnished the related press release as Exhibit 99.1.
The information in this report and Exhibit 99.1 is being furnished, not filed, under Item 2.02 of Form 8-K. Item 9.01 lists the exhibits, including Exhibit 99.1 and the Inline XBRL cover page labeled as Exhibit 104.
Exact Sciences (EXAS) reported an insider transaction: a director sold shares in an open-market trade. On 10/24/2025, the reporting person sold 12,000 shares of common stock at $65 per share under a pre-arranged Rule 10b5-1 trading plan entered on 11/25/2024. Following the sale, the individual beneficially owns 60,759 shares, held directly.
Insider transaction summary: An officer of Exact Sciences Corporation sold 1,500 shares of common stock on
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
